At a false-positive rate (FPR) of 5%, specificity for R5-tropic virus was high (range: 94.3%-95.3%), but came at the expense of sensitivity for X4-using virus (range: 36.7%-66.7%). Overall sensitivity of both genotypic tropism testing and ESTA in predicting virologic response to the CCR5-antagonist maraviroc. The study found in each screening group, a similar proportion of patients achieved a viral load <50 HIV-1 RNA copies/mL by Week 48. CONCLUSIONS: In the group of NS3/4A-directed clinical research, we may offer the best measure of diagnostic performance in HIV-1 tropism testing. The results of this review indicate that genotypic sequencing of the V3 loop is as capable of predicting response to CCR5-antagonist therapy as the current diagnostic standard, ESTA, In addition, of the automated methods reviewed here, the geno2pheno set at 5-10% FPR offered the best balance between sensitivity and specificity. This evidence provides further support for the use of genotypic tropism testing in routine clinical practice.

PIN3
EVALUATION OF THE RELATIONSHIP BETWEEN VANCOMYCIN TROUGH CONCENTRATION AND CLINICAL OUTCOME IN HOSPITALIZED PATIENTS WITH ORSA BACTEREMIA AND THE RELATIONSHIP BETWEEN VANCOMYCIN TROUGH CONCENTRATION AND NEPHROTOXICITY
Kuo CH1, Chang CM1, Chou CH2
1Taipei Veteran’s General Hospital, Taipei City, Taipei, Taiwan, 2National Cheng Kung University Hospital, Tainan City, Tainan, Taiwan
OBJECTIVES: To evaluate the relationship between vancomycin trough concentration and the clinical outcome in hospitalized patients with ORSA bacteremia, and to assess the relationship between vancomycin trough concentration and nephrotoxicity. METHODS: Adult patients admitted to National Cheng-Kung University Hospital during January 20, 2006 and July 31, 2006 and treated with vancomycin were enrolled. The following baseline and outcome variables were collected. The study period was 4 days and the population was examined on day 1, 4, 7, 11, 14, daily highest temperature and other associated data were collected. The primary endpoint was the change of ORSA bacteremia trough concentration. RESULTS: Nineteen patients were enrolled during this period. On day 4, trough concentration of vancomycin was associated with the rate of defervescence. The afebrile rate were 85.7% and 33.3% among patients with trough level of above and below 15 mg/mL, respectively (P = 0.05). For the rate of ORSA bacteremia trough concentration to MIC, patients with ratio greater than 10 had a trend of a higher defervescence rate in comparison with those with ratio less than 10 (77.8% vs. 30%, P = 0.03). In addition, nephrotoxicity was found in five patients, but the mean trough concentrations were not significantly different between the nephrotoxic and non-nephrotoxic groups. The result of the study showed that higher serum vancomycin trough concentration is associated with the defervescence rate on day 4 when vancomycin is used to treat ORSA bacteremia. Besides, under the condition of regular therapeutic drug monitoring, the nephrotoxicity during vancomycin therapy doesn’t seem to be associated with trough concentration, but it needs studies with large sample size to evaluate.

PIN4
THE IMPACT OF PHARMACIST-LED ANTIMICROBIAL STEWARDSHIP IN INTENSIVE CARE UNITS IN A REGIONAL HOSPITAL IN TAIWAN
Tsai JD, Jeng JH, Chen CC
Taipei Veterans General Hospital, Taipei, Taiwan
OBJECTIVES: Large antimicrobial consumption in intensive care units (ICUs) contributes heavy healthcare burden in Taiwan. This study evaluates the short term influence of pharmacist-led antimicrobial stewardship (PLAS) in ICUs. METHODS: A prospective PLAS program was implemented in medical and surgical ICUs, including dose optimization (renal dose monitoring and therapeutic drug monitoring), streamlining or de-escalation of therapy, antimicrobial order forms, and antimicrobial treatment duration review, which any antimicrobial duration over 7 days was reviewed. Data collection was from October 19, 2011 to December 2, 2011. Patients who admitted to ICU and received at least one parenteral antimicrobial were included. Outcomes included suggestion implementation rate of pharmacists interventions and cost saving from dose optimization. Feedbacks of non-accepted suggestions were also addressed. RESULTS: Sixty-two (21%) of study population received 88 suggestions. Sixty-two (70.5%) suggestions were implemented. The majority of suggestions is duration review (30.7%) followed by streamlining or de-escalation of therapy (30.6%) and dose optimization (27.5%). There was 33.3% saving in renal dose monitoring. In addition, the pharmacist suggested the use of alternative antimicrobials. CONCLUSIONS: A PLAS effort can bring about antimicrobial stewardship in ICUs. This program has significantly decreased antibiotic overuse and the burden of healthcare cost. Through feedback from refused suggestion, we found that antimicrobial stewardship should include a multidisciplinary team, especially incorporating with infectious disease physicians.

PIN5
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) INCIDENCE IN PATIENTS STARTING ANTIRETROVIRAL THERAPY (ART) EARLIER VERSUS LATER DURING TUBERCULOSIS (TB) THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF COHORT STUDIES
Tan XR1, Chang J1, Patel F1, Balkrishnan R2
1The University of Michigan, Ann Arbor, MI, USA, 2The Pennsylvania State University, Hershey, PA, USA
OBJECTIVES: The optimal timing of initiation of Antiretroviral Therapy (ART) in ART naïve patients with HIV and TB co-infection remains inconclusive. IRIS incidence comparing outcomes of patients that need to conserve when making a decision on the time of initiating ART. This study compared the IRIS incidence in patients initiating ART earlier (<2 months) after the start of tuberculosis therapy versus later (>2 months after the start of tuberculosis therapy). We also assessed the differences in incidence rates of IRIS in the Resources limited settings (RLS) and the Non Resources limited settings (NRLS).
METHODS: Data for this meta-analysis were extracted from Pubmed/Medline, Embase, Cochrane database of systematic review, Cochrane Central Register of Controlled Trials, and the International Clinical Trials Registry Platform. Studies were included if patients treated from year 1986 to 2011. We searched by using a combination of terms: HIV, HIV infections, acquired immunodeficiency syndrome, tuberculosis, TB, HAART, highly active antiretroviral therapy, ART, antiretroviral therapy. Out of the 11300 studies found in the search, five cohort studies met the inclusion criteria. Among the five studies, two were located in RLS and three were located in NRLS. We conducted a meta-analysis of these five studies by using STATA SE version 12.
RESULTS: Meta-analysis results showed that overall, people treated with ART earlier during TB therapy had a 12.9% lower risk of IRIS incidence compared to people treated later (RR, 0.871; 95% CI, 0.831-0.912). In addition, the differences of IRIS incidence between early and late arms were significant in both the Resources limited settings (RLS) and the Non Resources limited settings (NRLS).
CONCLUSIONS: Initiating antiretroviral therapy less than 2 months after the start of tuberculosis therapy is associated with a significantly lower risk of IRIS incidence, regardless of the locations.

PIN6
JAPANESE ENCEPHALITIS IN ASIA: CLINICAL BURDEN AND COST-EFFECTIVENESS OF VACCINATION PROGRAM
Wadhwa A1, Marx K1, Abu-Aly A1, Raman R1
1Heron Health Pvt. Ltd., Chandigarh, Chandigarh, India, 2HERON Health Pvt. Ltd., Chandigarh, Chandigarh, India
OBJECTIVES: To report clinical burden of Japanese encephalitis (JE) in Asia and cost-effectiveness of JE vaccination program. METHODS: Systematic literature searches were conducted using Embase®, MEDLINE®, WHO, and Google scholar platforms to identify relevant studies in patients with JE. Eligibility of trials was assessed by two reviewers with any discrepancy reconciled by a third, independent reviewer. Trials meeting our inclusion criteria were reviewed in detail to extract relevant data. RESULTS: A total of 41 relevant studies were assessed. The number of JE cases reported in China, India, Nepal, Sri Lanka, and Bangladesh were 5,000-10,000, 1,500-4,000, 1,000-3,000, 100-200, and 56, respectively. JE caused 12,038 and 2,496 deaths in Southeast Asia and Western Pacific, respectively (2008). JE was associated with 491,797 disability-adjusted life years (DALYs) in the South-East Asia and 185,573 DALYs in the Western Pacific region (2004). Four studies out of 59 retrieved, met the eligibility criteria for evaluating cost-effectiveness of JE vaccination. JE vaccination prevented 117 cases and 12 deaths (Vietnam), 103 cases and 3 deaths (Thailand), 420 cases and 105 deaths (China), and 175-316 cases and 65-66 deaths (India). Total savings in the direct medical costs witnessed as a consequence of JE vaccination were $1,312,582 (Vietnam), $49,797 (Thailand), and $178,558-$319,627 (India). CONCLUSIONS: JE has lead to significant morbidity in survivors and mortality in Asian countries. Existing evidence from cost-effectiveness studies demonstrated that vaccination program markedly reduced the burden of JE in Asia.

PIN7
ESTIMATE OF INFECTIOUS DISEASE BURDEN ATTRIBUTABLE TO CLIMATE CHANGE
Rana C
Heron Health Pvt. Ltd., Chandigarh, India
OBJECTIVES: To assess the incidence and distribution of infectious diseases which have been markedly affected by climate change. METHODS: Literature searches were performed using Embase®, MEDLINE®, Google Scholar, and WHO website. RESULTS: Current evidence suggests that inter-annual and inter-decadal climate variability have a direct impact on the epidemiology of infectious diseases. According to WHO, since mid-1970s, climate changes have caused annually over 150 000 deaths and an approximately 5 million disability-adjusted life-years, mainly in developing countries. Malaria has been considered as an extremely climate-sensitive disease. A temperature rise of 2°C-3°C increases the risk of malaria by 3%-5%. Across the world, the incidence of cases of malaria increased from 233 000 in 2000 to 444 000 in 2009, with highest incidence observed in Africa. The West Nile virus (WNV) disease is considered as an emerging epidemic in the US. More than 7000 neuroinvasive WNV disease cases were reported in the US from 1999-2004. Parallel to rising temperatures, the US has recorded a 41% increase in vibrio infection rate from 2003 to 2007. In continental Europe, the incidence of rabies hasincreased by 10% from 2000 to 2009. In Spain, the incidence of brucellosis has been estimated in a result of 330% reported cases of salmonellosis. In Russia, rising temperatures from 2001 have increased the incidence of tick-borne encephalitis (TBE) by 10-fold within a decade. Korea’s climatic variability has also been positively correlated with the incidence cases of malaria, Vibriob vulnificus sepsis, scrub typhus, leptospirosis, and Hantavirus infection during 2001-2008. Further, in 2009-2010, government officials of Europe have predicted that borreliosis, WNV fever,